News | July 09, 2009

Economy Forces European Institutions to Select Lower-Priced Interventional Cardiology Devices

July 9, 2009 – According to Millennium Research Group (MRG), the ongoing economic crisis is putting pressure on publicly funded European healthcare systems, intensifying the decline of interventional cardiology device prices in the region.

MRG's “European Markets for Interventional Cardiology Devices 2009 (Part II)” report details the extent to which competitive pricing and discounts among interventional cardiology device vendors is resulting in price erosion in Belgium, Luxembourg, the Netherlands, Norway, Denmark, Finland, Sweden, Spain and Switzerland.

IC device vendors are engaging in price undercutting and offering high-volume discounts or bundling deals with other products in their portfolios in order to encourage sales, resulting in price erosion. The healthcare systems in the Netherlands and Switzerland (beginning in 2012) provide only general funding for IC procedures, despite the varying cost of devices used. In order to operate within set budgets, European healthcare facilities must often choose lower-cost devices. Contract tenders between sellers and group purchasing organizations will further add to price erosion. In exchange for high-volume sales of their products, manufacturers offer significant discounts. This method of business is becoming more common across Europe, particularly in the Nordic countries and Spain.

MRG's new report provides important insight into the reasons behind and extent of the changes in interventional cardiology device pricing. Additionally, the report provides full breakdowns of procedures by type and device unit sales by subtype, including five-year forecasts, up-to-date market shares and in-depth qualitative insights.

For more information: www.MRG.net

Related Content

Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Overlay Init